Article
Cancer-associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin-L and tumor cell invasion.
BMC cancer - 12 May 2021
Sankpal Narendra V, Brown Taylor C, Fleming Timothy P, Herndon John M, Amaravati Anusha A, Loynd Allison N, Gillanders William E
Abstract excerpt
BACKGROUND: EpCAM (Epithelial cell adhesion molecule) is often dysregulated in epithelial cancers. Prior studies implicate EpCAM in the regulation of oncogenic signaling pathways and epithelial-to-mesenchymal transition. It was recently demonstrated that EpCAM contains a thyroglobulin type-1 (TY-1) domain. Multiple proteins with TY-1 domains are known to inhibit cathepsin-L (CTSL), a cysteine protease that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.